Civic Intelligence

Industry Pharmacogenomics Working Group C/O Contreras Legal Strategy LLC

990EZ • Fiscal year 2018 • EIN 83-0847467

Jan 01, 2018 to Dec 31, 2018

Washington, DC
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

47th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2018 filings • 501(c)6 • <$500k nonprofits • Source year 2018

Liabilities / Revenue

47th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2018 filings • 501(c)6 • <$500k nonprofits • Source year 2018

Net Margin

99th percentile

93%

Higher net margin than 99% of similar nonprofits.

2018 filings • 501(c)6 • <$500k nonprofits • Source year 2018

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2018

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2018

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2018

Assets

$126,964

No earlier filing loaded for comparison.

Net Assets

-

No earlier filing loaded for comparison.

Liabilities

$0

No earlier filing loaded for comparison.

Revenue

$136,000

No earlier filing loaded for comparison.

Expenses

$9,036

No earlier filing loaded for comparison.

Net Income

$126,964

No earlier filing loaded for comparison.

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$300K$200K$100K$0Assets 2018: $126,964Liabilities 2018: $02018Assets 2019: $169,373Liabilities 2019: $02019Assets 2020: $234,969Liabilities 2020: $0Net Assets 2020: $234,9692020Assets 2021: $265,911Liabilities 2021: $0Net Assets 2021: $265,9112021Assets 2022: $230,874Liabilities 2022: $0Net Assets 2022: $230,8742022Assets 2023: $262,032Liabilities 2023: $02023Assets 2024: $268,369Liabilities 2024: $0Net Assets 2024: $268,3692024

Highlighted filing

2018

Assets$126,964
Liabilities$0
Net Assets-

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$150K$100K$50K$0-$50KRevenue 2018: $136,000Expenses 2018: $9,036Net Income 2018: $126,9642018Revenue 2019: $103,985Expenses 2019: $61,576Net Income 2019: $42,4092019Revenue 2020: $119,919Expenses 2020: $54,323Net Income 2020: $65,5962020Revenue 2021: $116,985Expenses 2021: $86,043Net Income 2021: $30,9422021Revenue 2022: $79,952Expenses 2022: $114,989Net Income 2022: -$35,0372022Revenue 2023: $120,092Expenses 2023: $88,934Net Income 2023: $31,1582023Revenue 2024: $109,962Expenses 2024: $103,625Net Income 2024: $6,3372024

Highlighted filing

2018

Revenue$136,000
Expenses$9,036
Net Income$126,964
Filing Detail Status

This 2018 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

Jump To
Filing Snapshot
Filing Period
Jan 1, 2018 to Dec 31, 2018
Mission and Program Overview

Mission

To improve patient care through integration of pharmacogenomics in drug development.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings